BCL2L1 and neoplasm: We also presented the first in vivo proof-of-concept evidence to support the efficacy of combination BCL-2/BCL-xL BH3 mimetic with EGFR TKI in circumventing early adaptive drug resistance and thus resulting in durable tumor response in EGFR-mutant NSCLC precision therapy [13].